Trial Profile

A Phase 1 Study of JNJ-87189401 (PSMA-CD28 Bispecific Antibody) Combined With JNJ-78278343 (KLK2-CD3 Bispecific Antibody) for Advanced Prostate Cancer

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 05 Apr 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs JNJ 87189401 (Primary) ; Pasritamig (Primary)
Indications Adenocarcinoma; Neuroendocrine carcinoma; Prostate cancer
Focus Adverse reactions; First in man
Sponsors Janssen Research & Development

Most Recent Events

10 Feb 2025 Planned End Date changed from 21 Jun 2027 to 27 Oct 2027.
21 Oct 2024 Planned number of patients changed from 110 to 130.
17 Sep 2024 Trial design presented at the 49th European Society for Medical Oncology Congress, enrollment (approx. 110) is ongoing.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com